Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accounts Payables (2016 - 2025)

Heron Therapeutics' Accounts Payables history spans 14 years, with the latest figure at $9.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 23.19% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $9.0 million, down 23.19%, while the annual FY2025 figure was $9.0 million, 23.19% down from the prior year.
  • Accounts Payables reached $9.0 million in Q4 2025 per HRTX's latest filing, down from $12.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $13.8 million in Q2 2022 to a low of $559000.0 in Q4 2023.
  • Average Accounts Payables over 5 years is $7.1 million, with a median of $7.4 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: plummeted 85.82% in 2023, then skyrocketed 1994.63% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $3.8 million in 2021, then fell by 15.2% to $3.2 million in 2022, then crashed by 82.67% to $559000.0 in 2023, then surged by 1994.63% to $11.7 million in 2024, then dropped by 23.19% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Accounts Payables are $9.0 million (Q4 2025), $12.0 million (Q3 2025), and $12.0 million (Q2 2025).